Literature DB >> 29408267

Arginase-1 expressing microglia in close proximity to motor neurons were increased early in disease progression in canine degenerative myelopathy, a model of amyotrophic lateral sclerosis.

Christine M Toedebusch1, John C Snyder2, Maria R Jones3, Virginia B Garcia4, Gayle C Johnson5, Eric L Villalón3, Joan R Coates6, Michael L Garcia7.   

Abstract

Toxicity within superoxide dismutase-1 (SOD1)-associated familial amyotrophic lateral sclerosis (ALS) is non-cell autonomous with direct contribution from microglia. Microglia exhibit variable expression of neuroprotective and neurotoxic molecules throughout disease progression. The mechanisms regulating microglial phenotype within ALS are not well understood. This work presents a first study to examine the specific microglial phenotypic response in close association to motor neurons in a naturally occurring disease model of ALS, canine degenerative myelopathy (DM). Microglia closely associated with motor neurons were increased in all stages of DM progression, although only DM Late reached statistical significance. Furthermore, the number of arginase-1 expressing microglia per motor neuron were significantly increased in early stages of DM, whereas the number of inducible nitric oxide synthase (iNOS)-expressing microglia per motor neuron was indistinguishable from aged controls at all stages of disease. Fractalkine, a chemotactic molecule for microglia, was expressed in motor neurons, and the fractalkine receptor was specifically localized to microglia. However, we found no correlation between microglial response and lumbar spinal cord fractalkine levels. Taken together, these data suggest that arginase-1-expressing microglia are recruited to the motor neuron early in DM disease through a fractalkine-independent mechanism.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALS; Degenerative myelopathy; Fractalkine; Microglia; Motor neuron; Neurodegenerative disease

Mesh:

Substances:

Year:  2018        PMID: 29408267     DOI: 10.1016/j.mcn.2018.01.009

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  6 in total

1.  Asperosaponin VI ameliorates the CMS-induced depressive-like behaviors by inducing a neuroprotective microglial phenotype in hippocampus via PPAR-γ pathway.

Authors:  Xue Jiang; Saini Yi; Qin Liu; Dapeng Su; Liangyuan Li; Chenghong Xiao; Jinqiang Zhang
Journal:  J Neuroinflammation       Date:  2022-05-24       Impact factor: 9.587

2.  Lumbar spinal cord microglia exhibited increased activation in aging dogs compared with young adult dogs.

Authors:  Christine M Toedebusch; Virginia B Garcia; John C Snyder; Maria R Jones; David J Schulz; Gayle C Johnson; Eric Villalón; Joan R Coates; Michael L Garcia
Journal:  Geroscience       Date:  2019-12-11       Impact factor: 7.713

3.  The Dog Model in the Spotlight: Legacy of a Trustful Cooperation.

Authors:  Inès Barthélémy; Christophe Hitte; Laurent Tiret
Journal:  J Neuromuscul Dis       Date:  2019

4.  Modulating microglia activation prevents maternal immune activation induced schizophrenia-relevant behavior phenotypes via arginase 1 in the dentate gyrus.

Authors:  Yucen Xia; Zhiqing Zhang; Weipeng Lin; Jinglan Yan; Chuan'an Zhu; Dongmin Yin; Su He; Yang Su; Nenggui Xu; Robert William Caldwell; Lin Yao; Yongjun Chen
Journal:  Neuropsychopharmacology       Date:  2020-06-29       Impact factor: 7.853

5.  IL4-driven microglia modulate stress resilience through BDNF-dependent neurogenesis.

Authors:  Jinqiang Zhang; Peijing Rong; Lijuan Zhang; Hui He; Tao Zhou; Yonghua Fan; Li Mo; Qiuying Zhao; Yue Han; Shaoyuan Li; Yifei Wang; Wan Yan; Huafu Chen; Zili You
Journal:  Sci Adv       Date:  2021-03-17       Impact factor: 14.136

Review 6.  Nearly 30 Years of Animal Models to Study Amyotrophic Lateral Sclerosis: A Historical Overview and Future Perspectives.

Authors:  Tiziana Bonifacino; Roberta Arianna Zerbo; Matilde Balbi; Carola Torazza; Giulia Frumento; Ernesto Fedele; Giambattista Bonanno; Marco Milanese
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.